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Abstract
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited cardiac disease characterized by arrhythmias 
under adrenergic stress. Mutations in the cardiac ryanodine receptor (RYR2) are the leading cause for CPVT. We charac-
terized electrophysiological properties of CPVT patient-specific induced pluripotent stem cell-derived cardiomyocytes 
(hiPSC-CMs) carrying different mutations in RYR2 and evaluated effects of carvedilol and flecainide on action potential 
(AP) and contractile properties of hiPSC-CMs. iPSC-CMs were generated from skin biopsies of CPVT patients carrying 
exon 3 deletion (E3D) and L4115F mutation in RYR2. APs and contractile movement were recorded simultaneously from 
the same hiPSC-CMs. Differences in AP properties of ventricular like CMs were seen in CPVT and control CMs: APD90 of 
both E3D (n = 20) and L4115F (n = 25) CPVT CMs was shorter than in control CMs (n = 15). E3D-CPVT CMs had shortest 
AP duration, lowest AP amplitude, upstroke velocity and more depolarized diastolic potential than controls. Adrenaline had 
positive and carvedilol and flecainide negative chronotropic effect in all hiPSC CMs. CPVT CMs had increased amount of 
delayed after depolarizations (DADs) and early after depolarizations (EADs) after adrenaline exposure. E3D CPVT CMs 
had the most DADs, EADs, and tachyarrhythmia. Discordant negatively coupled alternans was seen in L4115F CPVT CMs. 
Carvedilol cured almost all arrhythmias in L4115F CPVT CMs. Both drugs decreased contraction amplitude in all hiPSC 
CMs. E3D CPVT CMs have electrophysiological properties, which render them more prone to arrhythmias. iPSC-CMs pro-
vide a unique platform for disease modeling and drug screening for CPVT. Combining electrophysiological measurements, 
we can gain deeper insight into mechanisms of arrhythmias.
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Introduction
Human induced pluripotent stem cells (hiPSCs) can be gen-
erated from patients’ somatic cells providing endless source 
for research in vitro [1]. The hiPSCs carry the same muta-
tions as the patient who donated the primary cells and the 
differentiation of disease specific hiPSC-derived cardiomyo-
cytes (CMs) allows disease modeling and drug development 
in human cells for personalized medicine.
Catecholaminergic polymorphic ventricular tachycardia 
(CPVT) is a severe inherited cardiac disease in structurally 
normal heart associated with risk of sudden cardiac death 
[2]. CPVT patients have arrhythmias during mental or physi-
cal stress. CPVT is caused by mutations mainly in the RYR2 
gene, coding for cardiac ryanodine receptor (RYR), but also 
mutations in other genes have been observed [3]. Therapy 
includes drug treatment, usually with beta-blockers, and, in 
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severe cases, implantable cardiac defibrillators or left car-
diac sympathetic denervation. However, present therapeutic 
options do not provide complete protection against poten-
tially lethal arrhythmias. A beta-blocker carvedilol and class 
Ic antiarrhythmic agent flecainide have been shown to have 
a direct effect on RYR and they, or their derivatives, are 
investigated as treatment options for CPVT [4–7].
CM contraction is driven by action potential (AP) 
induced release of intracellular  Ca2+ from sarcoplasmic 
reticulum (SR) [8]. Inward current through sodium chan-
nels  (INa) depolarizes the CM cell membrane which triggers 
inward flow of  Ca2+ through l-type calcium channels  (ICa,L), 
which leads to activation of RYRs and calcium induced cal-
cium release (CICR) from SR.  Ca2+ binds to sarcomeres 
and allows the contractile motion. Cell membrane is repo-
larized by several potassium currents and  Ca2+ is reloaded 
into SR via SR  Ca2+ ATPase (SERCA) [9]. The membrane 
potential  (Vm) and intracellular  Ca2+ concentration  [Ca2+]i 
are the most crucial elements in cardiac excitation contrac-
tion coupling (ECC) and arrhythmogenesis. The  [Ca2+]i 
influences the shape and duration of AP via  Ca2+-sensitive 
ionic transporters, such as  ICa,  Na+-Ca2+ exchanger (NCX) 
and  Ca2+-activated nonselective cation channels, thereby 
modifying the electrophysiological properties for example 
refractoriness and membrane depolarization rate [9]. Con-
versely, membrane potential can influence the  Ca2+ spark 
and waves [10].
A few studies have been focused on simultaneous record-
ing of  Vm, calcium transients or contractile function from 
the same hiPSC CMs [11–19]. It is important to understand 
the highly inter-related nature between these key elements in 
ECC. The ability to combine ionic and biomechanic analysis 
can offer valuable details considering disease mechanisms, 
drug effects and arrhythmogenesis. In our previous studies, 
we have measured intracellular calcium, action potentials 
and field potentials from CPVT hiPSC CMs [20–23]. In 
this study, we combined current clamp recording with video 
imaging. We characterized electrophysiological and contrac-
tile properties of CPVT patient-specific hiPSC CMs carry-
ing different mutations in RYR2. In addition, we evaluated 
effects of carvedilol and flecainide, agents that are shown to 
affect RYR2, on APs and contractility of hiPSC-CMs.
Materials and methods
Patient‑specific human iPSC lines
In this study, two CPVT hiPSC lines were used carrying 
following RYR2 mutations: one with exon 3 deletion c.168-
301_c.273+722del1128 (E3D) and one with point mutation 
p.L4115F (c.12343C > T) (L4115F). Mutation nomenclature 
was based on RYR2 reference sequence NM_001035.2. 
Wild type hiPSC line from one healthy individual was used 
as a control cell line. Several clones were established from 
the individuals but one per each was used in this study for 
characterization. The ethical committee of Pirkanmaa Hos-
pital District approved collection of biopsies for generating 
patient-specific iPSC lines and written informed consent 
was obtained from all the donors (Aalto-Setälä R08070). 
Human iPSC-lines were established by sendai viral (Cyto-
Tune® iPS reprogramming kit, Thermo Fisher Scientific, 
Waltham, MA, USA) or retroviral transfection of OCT3/4, 
SOX2, KLF4 and c-MYC [1]. Characterization of hiPSC 
lines has been described previously [22].
Cardiac differentiation and dissociation
Differentiation into CMs was carried out by co-culturing 
hiPSCs with murine visceral endoderm-like (END-2) cells 
(prof. Mummery, Humbrecht Institute, Utrecht, The Neth-
erlands) (supplementary data) [24]. Human iPSCs formed 
spontaneously beating clusters after 15 days of co-culturing. 
Beating clusters were cut and isolated with scalpel and dis-
sociated with collagenase A (Roche Diagnostics) [24]. Not 
all beating hiPSC CM clusters dissociate into single cells, 
therefore resulting into suspension of mixed single cell CMs 
and small CM aggregates. These CMs were plated on glass 
coverslips coated with 0.1% gelatin.
Chemicals
All the drugs and chemicals for the experiments were pur-
chased from the Sigma-Aldrich unless otherwise specified. 
Potassium methanesulfonate (KMeSO4) was ordered from 
MP biomedicals (USA). Stock solutions for extracellular 
solution were prepared in 1 M concentration and refrigerated 
until use. Extracellular solution was made freshly by diluting 
stock solution (in mM): 143 NaCl, 4.8 KCl, 1.8  CaCl2, 1.2 
 MgCl2, 5 glucose and 10 HEPES (pH adjusted to 7.4 with 
NaOH). Intracellular solution was made and refrigerated 
(in mM): 132 KMeSO4, 4 EGTA, 20 KCl, 1  MgCl2 and 1 
 CaCl2 (pH adjusted to 7.2 with KOH). Adrenaline, carve-
dilol and flecainide were dissolved in Milli-Q™ water and 
stored frozen until diluted to the final concentration (1 μM, 
0.25 μM and 1,5 μM respectively) in extracellular solution 
at the day of the experiments. Amphotericin-B was dissolved 
in DMSO and diluted to intracellular solution to make a final 
concentration of 0.24 mg/mL. One drug (either carvedilol or 
flecainide) was used per each cardiomyocyte. Same cardio-
myocytes were not exposed to both drugs.
Simultaneous patch clamp and video imaging
Experiments were conducted on 30+ days old (from start 
of differentiation) hiPSC CMs which were plated on cover 
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slips no more than 7 days before the experiments. Extracel-
lular solution was heated to 36 ± 1 °C with an inline heater 
SH-27B controlled with a TC-324B controller unit (Warner 
instruments Inc., CT, USA). The perfusion was controlled by 
a gravity driven VC38 application system (ALA Scientific 
Instruments Inc., NY, USA). Patch pipettes (Harvard Appa-
ratus Ltd., Holliston, MA, USA) were freshly prepared using 
PC-10 micropipette puller and flame polished with MF-830 
microforge (both from Narishige Int., Tokyo, Japan). The 
patch electrodes had tip resistance of 1.8–2.2 MΩ with intra-
cellular solution. AP recordings and video imaging were 
performed simultaneously. For patch clamp experiment, per-
forated patch using Amphotericin B was performed to record 
AP in Axon Series 200B patch-clamp amplifier connected 
to Digidata 1440a AD/DA converter driven by pCLAMP 
10.2 software (all from Molecular devices LLC). APs were 
recorded in the gap-free mode in the current-clamp from the 
spontaneously beating hiPSC-CMs. Current-clamp record-
ings were digitally sampled at 20 kHz and filtered at 2 kHz 
using a low pass Bessel filter on the recording amplifier. 
Videos were captured with ANDOR iXon 885 EM-CCD 
camera (Andor Technology, Belfast, Northern Ireland) and 
a TH4-200 light source (Olympus, Tokyo, Japan). Video 
imaging was performed using an inverted Olympus IX70 
microscope using LCAch N PhC 0.40NA 20 × air objective 
(Olympus) and recorded with LiveAcquisition software 
(TILL Photonics, Munich, Germany). The videos were 
recorded as 30 s-long sweeps with 49-105FPS before and 
after drug administration. Without binning of the camera 
and relatively large active pixel size, the videos were not the 
highest FPS possible. After establishing the seal, minimum 
of 2 min was allowed for the cardiomyocytes to stabilize 
before recording the baseline condition. The pCLAMP soft-
ware was configured to perform the synchronization between 
patch clamp and video imaging system by receiving the syn-
chronization pulse (SP) from the camera: SPs were recorded 
alongside with APs, thus when SP stopped, the video imag-
ing was stopped.
Action potential and contraction analysis
Action potentials were analyzed with Origin™ 9.1 (Origin-
Lab Corp., Northampton, USA) to extract the action poten-
tial parameters. The hiPSC-CMs were categorized as ven-
tricular-like and atrial-like CMs when they showed APD90/
APD50 < 1.30 and APA > 80 mV, and APD90/APD50 > 1.35, 
respectively. The different arrhythmias shown in the Fig. 3 
were analyzed manually. DADs were defined as brief > 5 mV 
depolarizations in the root or close proximity of the AP at 
the terminal repolarization (Fig. 3e, g, h). We have earlier 
characterized the average DAD amplitude as 5–15% of the 
preceding AP [18]. EADs were identified as extra AP or con-
secutive AP burst after the initial AP (Fig. 3g, h). Alternans 
was identified as constant alternating APD (long-short-long) 
for ten beats or longer (Fig. 3i). Tachyarrhythmia was iden-
tified as a transient change in BPM (Fig. 3j). Frequency of 
DADs and EADs was calculated by dividing the number of 
arrhythmias with the recorded time in each condition. The 
contraction properties were analyzed with ImageJ (NIH) 
plugin Musclemotion [25] with its built-in noise reduction 
and automatic reference frame detection settings. Cell size 
was also measured with ImageJ. The analysis was conducted 
only after minimum of 2 min to let the cell and Aps stabilize.
Statistical analysis
Statistical analysis was carried out with SPSS software 
version 23 (SPSS, Chicago, IL, USA). Comparison within 
cell lines (before and after drug administration) were per-
formed with non-parametric Wilcoxon and between cell 
lines (cell line to cell line comparison) with non-parametric 
Mann–Whitney U tests with Dunn-Bonferroni post hoc. 
p < 0.05 was considered statistically significant. Correlation 
of different parameters was done with Pearson correlation 
test.
Results
Differences between CM aggregates and single cells
There were no significant differences between AP or con-
traction parameters between CM aggregates and single cells 
(Tables S1 and S2). In this dataset, 68% were CM aggregates 
and 32% were single CMs. An aggregate consisted usually 
of two or few cells connected to each other (Fig. 3a–d, i, 
j). Area of CM aggregate was larger than the average cell 
area of single CM, approximately 8280 μm2 and 5370 μm2 
respectively (Fig. S1). Single CMs were more spread out 
than the ones inside an aggregate (Fig. 3e–h). In addition, 
there was no significant correlation between cell area and 
any AP or contraction parameter. Therefore, results from 
aggregates and single cells were pooled.
Action potential parameters and compound effects
CMs were recorded in current clamp and AP parameters 
were extracted (Fig. 1). Most of the CMs were ventricu-
lar like with APD90/50 ratio lower than 1.30. Properties of 
atrial like hiPSC CMs are shown in Table S3. Nodal like 
CMs were very few in number (data not shown). Only ven-
tricular like CMs were studied further with adrenaline and 
then with either carvedilol or flecainide along with adren-
aline. Representable traces from compound effects are in 
Fig. 3a–f.
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At baseline, hiPSC CMs differed from one to another: 
L4115F-CPVT CMs had the highest beating rate, E3D-
CPVT CMs had the lowest APA and MDP (p < 0.05). Over-
all, APD90 and APA was lower and MDP more depolarized 
in CPVT compared to control CMs. Adrenaline had posi-
tive chronotropic effect on all hiPSC CMs: Beating rate was 
increased and APD10, 50 and 90 were decreased (p < 0.05). 
In addition, adrenaline decreased APA and depolarized MDP 
the most in E3D-CPVT CMs (p < 0.05). Furthermore, adren-
aline increased upstroke velocity (dVdT) and triangularity 
(APD ratio) in L4115F and WT CMs (p < 0.05) but not in 
E3D CPVT CMs. Carvedilol and flecainide both had nega-
tive chronotropic effect on all hiPSC CMs: decreased beating 
rate and increased APD90 (p < 0.05). In addition, both drugs 
decreased upstroke velocity and increased triangularity in 
CPVT CMs (p < 0.05). Carvedilol decreased beating rate 
the least but upstroke velocity the most in L4115F-CPVT 
CMs. Carvedilol had the least effect on APDs in control 
CMs. Flecainide decreased upstroke velocity the least but 
increased APD50 and 90 the most in L4115F CPVT CMs.
Contraction parameters and drug responses
Contraction properties of hiPSC CMs were studied 
with video imaging simultaneously along current clamp 
recording. Not all the videos could be analyzed in such a 
precision because of low signal to noise ratio, therefore 
the n amount in contraction parameters in Fig. 2 is less 
than in AP parameters in Fig. 1. In addition, the com-
parison of contraction amplitude (CTA) was not plausible 
between recordings because of variation in the lighting 
conditions affected by the liquid flow during each record-
ing. The preheated perfusate created a turbulent flow and 
small bubbles in the recording chamber resulting in dif-
fraction of light and different lighting and baseline condi-
tions for the intensity based peak detection. Therefore, 
only the compound effects as the change of CTA can be 
compared within one recorded cell. At baseline, CPVT 
CMs had shorter contraction duration at 90% of relaxa-
tion (CTD90) and relaxation time (Fig. 2). Adrenaline 
decreased CTDs, time to peak and relaxation time more 
in controls than CPVT CMs. Flecainide prolonged CTDs 
and relaxation time the most in control CMs. Both drugs 
decreased contraction amplitude the most in E3D CPVT 
CMs. Interestingly, flecainide decreased the relaxation 
time and CTDs only in E3D CPVT CMs. In addition, fle-
cainide decreased the CTA the most in E3D CPVT CMs. 
Carvedilol decreased the contraction amplitude more than 
flecainide in L4115F CPVT and control CMs but not in 
E3D CPVT CMs. Furthermore, carvedilol decreased CTDs 
the most in control CMs.
Fig. 1  Action potential parameters and compound effects on ventricu-
lar like control and CPVT hiPSC CMs. Bl = baseline, adr = adrena-
line, car = carvedilol, fle = flecainide. Number of cells recorded: E3D) 
bl = 20, adr = 20, car = 13, fle = 7; L4115F) bl = 25, adr = 25, car = 6, 
fle = 19; WT) bl = 15, adr = 15, car = 5, fle = 10. BPM = beats per 
minute, APD = action potential duration at given % of repolarization, 
APA = action potential amplitude, MDP = maximum diastolic poten-
tial, dVdT = upstroke velocity, APD90/50 = triangularity. *Indicates 
statistical significance (p < 0.05). Statistical comparisons were done 
between adr versus bl and car or fle versus adr. Error bars represent 
standard error of mean
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Correlation between AP and contraction
There was significant (p < 0.01) positive correlation between 
all respective APD and CTD parameters (Fig. S2). Figure 3 
merged sections show the interrelation between  Vm and con-
traction. Contraction follows  Vm in various arrhythmic con-
ditions. Weak but significant negative correlation between 
BPM and time to peak was found (p < 0.01) at baseline 
and adrenaline: time to peak decreases when beating rate 
increases. In addition, APD ratio and relaxation time also 
had weak and significant negative correlations (p < 0.01) at 
baseline and adrenaline: the smaller the ratio, the longer the 
relaxation time. After drug administration, the correlations 
were not as strong or significant anymore. Carvedilol and 
flecainide therefore had an impact on coupling of membrane 
 Vm and contraction.
Arrhythmias seen in patch clamp recording reflected 
on contraction
None of the control CMs had arrhythmias at adrenaline 
whereas all the CPVT CMs were arrhythmic. Overall, hiPSC 
CMs had more DADs than EADs (Fig. 4). Representative 
traces of different arrhythmias are presented in Fig. 3. E3D 
CPVT CMs had the most arrhythmias at all conditions. Fur-
thermore, CPVT CMs had increased amount of DADs and 
EADs after adrenaline exposure, however this result was not 
statistically significant (p > 0.05). DADs are seen as a swift 
depolarization immediately after repolarization (Fig. 3g). 
These minor changes in  Vm are not reflected in contraction 
profile. Phase 3 and burst EADs are present in both Vm 
and contraction (Fig. 3g, h). The extra beats resulting from 
EADs have decreased contraction amplitude. Both drugs 
were able to decrease the amount of DADs in CPVT CMs 
whereas flecainide slightly increased EADs in E3D CPVT 
CMs (Fig. 4). Carvedilol abolished almost all arrhythmias in 
L4115F CPVT CMs while flecainide decreased DADs 67% 
and EADs 49% (Fig. 3c–f). In addition, flecainide decreased 
DADs 60% and carvedilol 51% in E3D CPVT CMs. APD 
alternans was seen in 2/25 (8%) L4115F CPVT CMs after 
adrenaline as alternating APD in  Vm and amplitude in con-
traction (Fig. 3I). Long AP results in lower amplitude and 
vice versa. Flecainide abolished both of the alternans cases. 
Tachyarrhythmia were seen in 4/20 (20%) E3D CPVT CMs 
and 1/25 (4%) L4115F CPVT CMs as a rapid major change 
in beat rate and depolarized MDP continuing for over several 
seconds (Fig. 3j). Flecainide abolished one of the tachyar-
rhythmias, whereas it caused two CMs undergo tachyar-
rhythmia. Carvedilol abolished three of the four tachyar-
rhythmia cases.
Discussion
Following the discovery of linking RYR2 mutations to 
CPVT, studies utilizing patch clamp in RYR2-R4496C 
mutant mouse model have been published [2, 26–28]. 
Increased open probability of mutated RYR2 leading to 
spontaneous calcium release and lowered threshold for 
triggered activity has been identified as a primary cause 
Fig. 2  Contraction parameters and compound effects on ventricular 
like control and CPVT hiPSC CMs. Bl = baseline, adr = adrenaline, 
car = carvedilol, fle = flecainide. Number of cells recorded: E3D) 
bl = 18, adr = 18, car = 10, fle = 6; L4115F) bl = 23, adr = 23, car = 6, 
fle = 16; WT) bl = 11, adr = 11, car = 6, fle = 5. CTD = contraction 
duration at given percentage of relaxation, CTA = contraction ampli-
tude (normalized to control). The comparison of CTA is not plausi-
ble between different cells, only the proportional change of CTA can 
be compared. *Indicates statistical significance (p < 0.05). Statistical 
comparisons were done between adr versus bl and car or fle versus 
adr. Error bars represent standard error of mean
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Fig. 3  Representative traces of drug responses and arrhythmias in 
hiPSC CMs. Action potential and contraction measured simultane-
ously from the same cell. a Normal baseline trace of WT control, 
b normal adrenaline trace from the same cell as in (a, c) adrenaline 
trace from CPVT showing extra beat (arrow), d carvedilol trace from 
the same cell as in (c, e) adrenaline trace from CPVT showing DADs 
(arrows), f flecainide trace from the same cell as in (e, g) DADs and 
phase 3 EADs (arrows) from CPVT CM, h EAD burst and DADs 
(arrows) from CPVT CM, i alternans from CPVT CM where long AP 
(L) results in lower contraction amplitude (arrow) and short AP (S) in 
higher, j tachyarrhythmia from CPVT CM. Dashed lines at 0 mV
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for DADs and arrhythmia. Patch clamp recordings show-
ing DADs under isoproterenol or other adrenergic stimulus 
have confirmed this. However, electrophysiological proper-
ties of mouse and human CMs are different, e.g. beating rate 
and presence of repolarizing ionic currents [29]. Therefore, 
hiPSC derived CMs have been introduced, and electrophysi-
ology studies using CPVT patient derived hiPSC CMs have 
been published, and the disease phenotype has been con-
firmed in human-based cell model in vitro [23, 30–32].
In this study, we characterized electrophysiological prop-
erties of E3D and L4115F CPVT hiPSC-CMs and control 
CMs at baseline and after adrenaline provocation and eval-
uated antiarrhythmic effects of carvedilol and flecainide. 
CPVT CMs had shorter APD90 and more depolarized 
MDP compared to controls at baseline. The more depolar-
ized MDP led to lower APA in CPVT CMs. In addition, 
the shorter APD90 probably was caused by the sarcolem-
mal calcium transient affected via the leaky RYR2 mediated 
higher intracellular calcium concentration. Furthermore, 
MDP change affects the availability of ion channels at the 
cardiomyocyte membrane laying effect on the AP profile. 
Adrenaline had positive and carvedilol and flecainide nega-
tive chronotropic effect in all hiPSC CMs. CPVT CMs had 
increased number of DADs and EADs after adrenaline expo-
sure. Adrenaline provocation increases the SR calcium load 
and results to calcium leak via the mutated RYR2s. The 
results suggest that the depolarized MDP plays a role in the 
generation of arrhythmias in E3D CPVT CMs. Alternans 
was seen in L4115F CPVT CMs. Carvedilol and flecainide 
decreased the number of DADs but flecainide increased 
EADs in E3D CPVT and control CMs. In addition, both 
drugs decreased contraction amplitude in all hiPSC CMs.
CPVT CMs had more DADs than EADs
In this study, CPVT hiPSC CMs were more arrhythmic than 
control CMs (Fig. 4). In addition, there were more DADs 
than EADs in CPVT CMs. Carvedilol was more efficient 
abolishing EADs than flecainide (Fig. 4b). Carvedilol acts 
by blocking beta-adrenergic receptors, inhibiting phospho-
rylation of calcium handling proteins (RYR, SERCA,  ICa,L) 
and altering calcium handling. Flecainide acts by blocking 
sodium channels leading to reduced excitability, but also  IKr 
leading to risk for arrhythmia. In addition, both drugs have 
shown to reduce RYR2 calcium leak associated with DADs 
[4–7]. In this study, both drugs decreased the number of 
DADs in CPVT CMs (Fig. 4).
Novak et al. reported oscillatory prepotentials (OPPs), 
distinct from DADs, described as voltage oscillations dur-
ing late diastolic depolarization [32, 33]. This irregularity 
in the membrane potential is very similar to what have been 
earlier described as DADs [23, 27, 28, 30, 31]. In our current 
study, flecainide abolished majority of DADs but not all of 
them. In Fig. 3e, g, h, two kind of DADs appear: right after 
repolarization in the root of AP (Fig. 3e) and later in the 
diastolic depolarization (Fig. 3h). The latter hold a remark-
able resemblance to OPPs. Flecainide cured all of the first 
mentioned DADs, but only a portion of the latter. This could 
indicate distinctive ways these two types of DADs are pro-
duced. However, the APD prolongation caused by flecainide 
may mask the first type of DADs. Furthermore, some CMs 
exhibited long irregular periodical beating patterns (Fig. S3). 
There is similar voltage oscillation during OPPs and the gaps 
between these periods. This might be due to aberrant CM 
automaticity and different from the mechanism of DADs. 
Cells, which were beating inconsistently in this manner, 
were excluded from the further analysis.
E3D CPVT CMs: depolarized MDP and high DAD 
frequency
In this study, E3D CPVT CMs had the most DADs and 
EADs. The more positive, depolarized MDP seems to be 
favoring arrhythmic events by setting lower threshold for 
triggered activity. SR calcium leak through RYR can lead 
to small changes in membrane voltage leading to activation 
of  ICa,L or influx through NCX and eventually CICR, there-
fore causing premature action potential triggering and extra 
beats. Consequently, APA and upstroke velocity (dVdT) 
were also smaller in these cells.
In earlier studies, the exon 3 deletion in RYR2 leads 
to a severe clinical phenotype of CPVT [34–36]. At the 
protein level, exon 3 deletion causes a f lexible rear-
rangement in the cytosolic part of the RYR2 affecting 
domain–domain interactions inside the protein [35, 37]. 
Yet another study found the exon 3 deletion of RYR2 
to result in the abnormal termination of calcium release 
through the channel [38]. These aforementioned studies 
support our earlier study, where E3D CPVT patient was 
shown to have more polymorphic ventricular contractions 
at rest compared to the L4115F CPVT patient [20]. Simi-
larly, in this study there were more arrhythmias in E3D 
CPVT hiPSC CMs at baseline. In addition, similarly to 
this study, in that same earlier study, the beating rate of 
the E3D CPVT CMs was lower than the L4115F CPVT 
CMs [20]. Furthermore, in another of our previous stud-
ies, the expression of the RYR2 protein was confirmed 
and there was no difference between RYR2-P2328S 
CPVT and control CMs [23]. In that same study, frac-
tional SR calcium release was also found greater in those 
CPVT CMs compared to controls.
In our earlier calcium imaging study of the same E3D 
CPVT CMs, there were the most oscillating calcium tran-
sients, which were several seconds in duration, in these 
CMs [22]. That is probably why there is such a differ-
ence when comparing the calcium transient duration in 
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that study to APDs in this study. In addition, the beating 
rates of the CMs were different. Since the repolarization 
of AP is much more rapid than calcium decay, similar 
oscillation patterns were not detected in membrane volt-
age in this study. In addition, it could be that the CMs 
exhibiting periodical beating were the ones captured with 
the long calcium oscillations in the previous study, and 
in this study, they were not included in the ventricular 
like dataset. In addition, calcium imaging does not allow 
distinguishing between CM subtypes. Furthermore, the 
previous study showed that E3D CPVT CMs had lower 
calcium transient amplitude, which could be an indica-
tion of elevated diastolic calcium [22]. We returned to 
that calcium imaging dataset and analyzed the baseline 
fluorescence intensity values at diastole and indeed, in 
CPVT cells it was higher compared to the controls and the 
highest in E3D CPVT CMs (p < 0.001) (Fig. S4). These 
findings suggest that the RYR2 exon 3 deletion results in 
elevated diastolic calcium, which contributes to the depo-
larized diastolic potential therefore facilitating arrhythmic 
behavior in these cells.
Alternans
Similar to our previous study, L4115F CPVT CMs had 
alternans during adrenergic stress [22]. In this study, two 
alternans cases were recorded, both in L4115F CPVT CMs. 
Both of these were discordant, negatively coupled and elec-
tromechanically out of phase, in which the long AP results 
in low and short AP in high contraction amplitude (Fig. 3i). 
It has been shown with in silico modeling that in these cases 
the driving force of the alternans is unstable intracellular 
calcium [39]. In addition, the RYR2-L4115F point mutation 
is located in the central domain of the protein leading to gain 
of function of the channel and could therefore facilitate the 
formation of alternans via imbalanced calcium cycling [40]. 
In this study, we did not conduct calcium imaging but it is 
known from the previous studies that calcium and contrac-
tion go hand in hand [15]. Membrane voltage, calcium and 
contraction are tightly coupled in cardiac ECC. In addition 
to causing APD alternans, we showed that calcium alternans 
can cause very small scale MDP alternans leading to more 
negative MDP after a long AP and a bit more positive after a 
short one (Fig. S5). MDP changes between consecutive beats 
were only approximately 0.5 mV. This indicates that higher 
calcium content during longer calcium transient, associated 
with the short AP, contributes to the repolarization to a more 
positive MDP.
Contraction of hiPSC CMs
Contraction parameters were acquired by analyzing videos 
of beating CMs. Sampling interval at lower video frame rates 
can affect the accuracy of the analysis of rise time of the con-
traction peaks. We used larger active camera chip without 
binning to capture the whole cell area of the CMs and CM 
aggregates for the analyses. In addition, contraction param-
eters had relatively high deviation (Fig. 2). Consequently, 
there was a lack of statistical significance in these results. 
Figure 3 shows how different arrhythmias were recapitulated 
in contraction profile. EAD triggered extra beats were char-
acterized with lower contraction amplitude (Fig. 3g, h). Dis-
cordant negatively coupled alternans led to electromechani-
cally out of phase beating pattern (Fig. 3i). Tachyarrhythmia 
Fig. 4  Incidence of arrhythmias in hiPSC CMs. Bl = baseline, 
adr = adrenaline, car = carvedilol, fle = flecainide. Number of cells 
recorded: E3D) bl = 20, adr = 20, car = 13, fle = 7; L4115F) bl = 25, 
adr = 25, car = 6, fle = 19; WT) bl = 15, adr = 15, car = 5, fle = 10. 
EADs include phase 3 and burst EADs. *Indicates statistical signifi-
cance (p < 0.05). Statistical comparisons were done between adr ver-
sus bl and car or fle versus adr. Error bars represent standard error of 
mean
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elevated the baseline of contraction drastically but did not 
reduce contraction amplitude. Carvedilol decreased CTA, 
as a beta-blocker should, by reducing SR calcium load via 
inhibition of the adrenergic pathway. Carvedilol decreased 
the CTA more than flecainide in L4115F CPVT and control 
CMs, but not in E3D CPVT. This might be an indication of 
flecainide’s improved block of RYR2 carrying the deletion. 
In E3D CPVT CMs, flecainide might be compensating the 
absence of beta-blocker ability by increased RYR2 block 
therefore resulting in as strong CTA decrease as carvedilol. 
Flecainide decreased CTDs most in E3D CPVT CMs. At 
more positive diastolic potential, APs are driven more by 
calcium than at more negative diastolic potentials because 
 ICa,L open at more positive membrane potential than sodium 
channels. Interestingly, E3D CPVT CMs had higher contrac-
tion amplitude at baseline. Flecainide blocking both voltage 
gated sodium channels and RYR2 results in decreased CTDs 
and more decreased contraction amplitude compared to CMs 
with more repolarized MDP. Carvedilol, however, affects the 
SR calcium content by inhibition of adrenergic pathway and 
RYR2 block. The different pathways of action of these two 
drugs might explain the differences.
Future perspectives
Detailed investigation of electrophysiological properties 
of hiPSC CMs gives valuable information about arrhyth-
mic conditions and their triggers, even though they do 
not completely recapitulate the phenotype of adult human 
CMs. However, they can serve several different purposes, 
for example drug screening and disease modeling. In addi-
tion, more detailed and fine-tuned in silico models can be 
developed to simulate human cardiac/cardiomyocyte physi-
ology [41]. These cell models and approaches can be utilized 
by pharmacological industry to fulfil the need of more cost 
efficient and human-based drug development already in pre-
clinical phases. Human iPSC derived CMs can offer physi-
ologically more authentic model to study cardiotoxic effects 
in vitro, decrease the amount of animal studies and cut costs 
in the drug development process. Combining in vitro and in 
silico modeling will hopefully accelerate the cardiovascular 
research in the future.
Conclusions
In this study, simultaneous patch clamp and video imaging 
was conducted with CPVT patient derived hiPSC CMs to 
study effect of carvedilol and flecainide on AP and con-
tractile properties. Differences in baseline properties and 
drug effects were found. CPVT CMs were more arrhyth-
mic than controls. In addition, there were more DADs than 
EADs in the hiPSC CMs. The E3D CPVT CMs had the 
most arrhythmias and electrophysiological properties dis-
tinct from others favoring arrhythmic behaviour. Different 
types of arrhythmias in membrane voltage were reflected 
in the contraction profile of the CMs. In this study, there 
were still substantial amount of DADs present after drug 
administration, indicating these treatments provide only 
partial protection from arrhythmias. Therefore, it is impor-
tant to look for additional drug therapies for CPVT. Patient 
specific hiPSC CMs recapitulate disease hallmarks and 
drug responses therefore providing a powerful tool to 
study CPVT.
Limitations
In this study, only one clone per hiPSC line from a healthy 
donor was used to create control CMs. APD ratio was used 
to distinguish CM subtypes. However, controversy for the 
determination of the CM subtypes exists [42]. The imma-
turity of the hiPSC derived CMs, their calcium handling 
and electrophysiology; especially  IKf and  IK1 is still a rel-
evant problem [43]. Therefore, these results may not be 
translatable to patients. However, in our earlier studies, our 
hiPSC derived CMs have been characterized by various 
techniques showing their electrophysiological properties 
[18, 22, 23, 44].
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